Nesiritide

Overview

A cautionary tale worth reading before trusting any surrogate endpoint. Nesiritide was approved because it improved breathlessness scores and lowered filling pressures. When a 7,000-patient trial finally asked whether patients did better, the answer was no.

How it works

Identical to endogenous BNP. Binds natriuretic peptide receptor A, raising cyclic GMP to produce venous and arterial vasodilation, natriuresis and diuresis, and suppression of the renin-angiotensin-aldosterone and sympathetic systems.

Evidence base

Rated 5 of 5 — Very strong. Multiple phase 3 randomized trials plus regulatory approval in a major market.

• An approval based on surrogate endpoints, overturned in practice by a large outcomes trial — one of the best-documented examples in cardiology.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

• Reduces pulmonary capillary wedge pressure Strong evidence

  Rapid and reliable haemodynamic improvement — the physiology works exactly as designed.

• Small improvement in dyspnoea Moderate evidence

  ASCEND-HF found a statistically significant but clinically marginal improvement in self-reported breathlessness.

• No proarrhythmia Strong evidence

  Unlike inotropes such as milrinone or dobutamine, it does not increase arrhythmia burden.

• Validated the natriuretic peptide axis Moderate evidence

  The pathway itself proved therapeutically real, and was later exploited successfully by neprilysin inhibition.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

• No benefit on death or rehospitalisation Serious

  ASCEND-HF found no reduction in 30-day mortality or heart failure rehospitalisation. The surrogate endpoints that won approval did not translate.

• Hypotension Serious

  Significantly more common than with placebo, and often prolonged given the vasodilator mechanism.

• Earlier renal safety controversy Moderate evidence

  Meta-analyses raised concerns about worsening renal function; ASCEND-HF did not confirm renal harm but did not vindicate the drug either.

• High cost for no outcome benefit Moderate evidence

  Substantially more expensive than nitroglycerin, which performs comparably.

• Largely abandoned in practice Moderate evidence

  Guidelines no longer recommend routine use, and clinical use has collapsed.

Who should avoid it

• Cardiogenic shock
• Systolic blood pressure below 90 mmHg
• Suspected low filling pressures
• Valvular stenosis or constrictive pericarditis

If used under medical supervision, monitor

• Continuous blood pressure monitoring
• Renal function and electrolytes
• Symptom response and fluid balance

Interactions

Not exhaustive. Always have a pharmacist or physician review your full medication list — including supplements.

• ACE inhibitors — additive hypotension
• Other vasodilators — additive hypotension
• Note: BNP assays are confounded during infusion; NT-proBNP is unaffected

Regulatory & legal status

Prescription drug; approval retained but clinical use is minimal.

Infographic

Nesiritide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

• PubMed — all published literature on Nesiritide
• PubMed — randomized controlled trials only
• ClinicalTrials.gov — registered human trials
• DailyMed — official FDA prescribing information

Related peptides in Cardiac & Vascular